Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure

Proteomics

Volumn 10, Issue 19, 2010, Pages 3525-3532

  Mazouni, Chafika ^a,b   Baggerly, Keith ^c   Hawke, David ^c   Tsavachidis, Spyros ^c   André, Fabrice ^c   Buzdar, Aman U ^c   Martin, Pierre Marie ^c   Kobayashi, Ryuji ^c   Pusztai, Lajos ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Glycoproteomics; HER 2; MALDI TOF; Neoadjuvant chemotherapy

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMYLOID P COMPONENT; APOLIPOPROTEIN A1; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HEMOPEXIN; PACLITAXEL; PEPTIDE; PLASMA PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; TREATMENT RESPONSE;

BLOOD PROTEINS; BREAST NEOPLASMS; CHROMATOGRAPHY, LIQUID; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77957198343     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000057     Document Type: Article

References (22)

1. Boughey, J. C., Peintinger, F., Meric-Bernstam, F., Perry, A. C. et al., Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann. Surg. 2006, 244, 464-470.
2. Liedtke, C., Mazouni, C., Hess, K. R., Andre, F. et al., Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275-1281.
3. Mazouni, C., Kau, S.W., Frye, D., Andre, F. et al., Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann. Oncol. 2007, 18, 874-880.
4. Cho,W. C., Cheng, C. H., Oncoproteomics: current trends and future perspectives. Exp. Rev Proteomics 2007, 4, 401-410.
5. Fiedler, G. M., Leichtle, A. B., Kase, J., Baumann, S. et al., Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin. Cancer Res. 2009, 15, 3812-3819.
6. Findeisen, P., Zapatka, M., Peccerella, T., Matzk, H. et al., Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J. Clin. Oncol. 2009, 27, 2199-2208.
7. Shin, S., Cazares, L., Schneider, H., Mitchell, S. et al., Serum biomarkers to differentiate benign and malignant mammographic lesions. J. Am. Coll. Surg. 2007, 204, 1065-1071.
8. Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E. et al., A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 2007, 53, 1067-1074.
9. Pusztai, L., Gregory, B. W., Baggerly, K. A., Peng, B. et al., Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100, 1814-1822.
10. Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J. et al., Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J. Clin. Oncol. 2005, 23, 3676-3685.
11. Mazouni, C., Arun, B., André, F., Ayers, M. et al., Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br. J. Cancer 2008, 99, 68-71.
12. Mazouni, C., Hall, A., Broglio, K., Fritsche, H. et al., Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 2007, 109, 496-501
13. Coombes, K. R., Tsavachidis, S., Morris, J. S., Baggerly, K. A. et al., Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics 2005, 5, 4107-4117.
14. Pawlik, T. M., Hawke, D. H., Liu, Y., Krishnamurthy, S. et al., Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006, 6, 68.
15. Gonçalves, A., Esterni, B., Bertucci, F., Sauvan, R. et al., Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006, 25, 981-989.
16. Lane, D. M., Boatman, K. K., McConathy, W. J., Serum lipids and apolipoproteins in women with breast masses. Breast Cancer Res. Treat. 1995, 34, 161-169.
17. Huang, H. L., Stasyk, T., Morandell, S., Dieplinger, H. et al., Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006, 27, 1641-1650.
18. Engwegen, J. Y., Helgason, H. H., Cats, A., Harris, N. et al., Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 2006, 12, 1536-1544.
19. Steel, L. F., Shumpert, D., Trotter, M., Seeholzer, S. H. et al., A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma. Proteomics 2003, 3, 601-609.
20. Zhang, Z., BastJr, R. C., Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
21. Ohshiro, K., Rosenthal, D. I., Koomen, J. M., Streckfus, C. F. et al., Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma. Int. J. Oncol. 2007, 30, 743-749.
22. Doustjalali, S. R., Yusof, R., Yip, C. H., Looi, L. M. et al., Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors. Electrophoresis 2004, 25, 2392-2401.